Pulmonary function testing prior to hematopoietic stem cell t ransplantation

Bone Marrow Transplantation

Volumn 35, Issue 5, 2005, Pages 429-435

  Chien, J W ^a,b   Madtes, D K ^a,b   Clark, J G ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG COMPLICATION; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG VOLUME; MORTALITY; PATIENT CARE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SPIROMETRY; STANDARD; TREATMENT PLANNING;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG DISEASES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT;

EID: 15544386480     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704783     Document Type: Article

References (68)

1. Patriarca F, Skert C, Sperotto A et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004; 33: 751-758.
2. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-434.
3. Gopal R, Ha CS, Tucker SL et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92: 1949-1958.
4. Ozsahin M, Pene F, Touboul E et al. Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients. Cancer 1992; 69: 2853-2865.
5. Szekely J, Fabry L, Forgacs G et al. Total body irradiation before bone marrow transplantation. Technique and acute toxicity. Strahlenther Onkol 1999; 175: 606-610.
6. Kader HA, Khanna S, Hutchinson RM et al. Pulmonary complications of bone marrow transplantation: the impact of variations in total body irradiation parameters. Clin Oncol (R Coll Radiol) 1994; 6: 96-101.
7. Rossi SE, Erasmus JJ, McAdams HP et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20: 1245-1259.
8. Helman Jr DL, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 2002; 122: 785-790.
9. Ozsahin M, Belkacemi Y, Pene F et al. Interstitial pneumonitis following autologous bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation. Int J Radiat Oncol Biol Phys 1996; 34: 71-77.
10. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851-1856.
11. Gulbahce HE, Manivel JC, Jessurun J. Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow transplantation. Am J Surg Pathol 2000; 24: 1147-1152.
12. Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989; 47: 989-992.
13. Williams LM, Fussell S, Veith RW et al. Pulmonary venoocclusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 1996; 109: 1388-1391.
14. Mathew P, Bozeman P, Krance RA et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 221-223.
15. Thirman MJ, Devine SM, O'Toole K et al. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10: 307-311.
16. Kleinau I, Perez-Canto A, Schmid HJ et al. Bronchiolitis obliterans organizing pneumonia and chronic graft-versus-host disease in a child after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 841-844.
17. Kanda Y, Takahashi T, Imai Y et al. Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1997; 19: 1251-1253.
18. Silliman CC, Paterson AJ, Dickey WO et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37: 719-726.
19. Silliman CC, Boshkov LK, Mehdizadehkashi Z et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101: 454-462.
20. Weiner RS, Dicke KA. Risk factors for interstitial pneumonitis following allogeneic bone marrow transplantation for severe aplastic anemia: a preliminary report. Transplant Proc 1987; 19 2639-2642.
21. Wingard JR, Mellits ED, Sostrin MB et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore) 1988; 67: 175-186.
22. Wingard JR, Sostrin MB, Vriesendorp HM et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46: 61-65.
23. Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1393-1400.
24. Crawford SW, Longton G, Storb R. Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1993; 12: 225-231.
25. Robbins RA, Linder J, Stahl MG et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989; 87: 511-518.
26. Wojno KJ, Vogelsang GB, Beschorner WE, Santos GW. Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease. Transplantation 1994; 57 88-92.
27. Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000; 26: 539-543.
28. Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166: 1364-1368.
29. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-376.
30. Clark JG, Schwartz DA, Flournoy N et al. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-656.
31. Curtis DJ, Smale A, Thien F et al. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 169-173.
32. Wyatt SE, Nunn P, Hows JM et al. Airways obstruction associated with graft versus host disease after bone marrow transplantation. Thorax 1984; 39: 887-894.
33. Philit F, Wiesendanger T, Archimbaud E et al. Post-transplant obstructive lung disease ('bronchiolitis obliterans'): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8: 551-558.
34. Chien JW, Martin PJ, Flowers ME et al. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 759-764.
35. Chien JW, Martin PJ, Gooley TA et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-214.
36. Ostrow D, Buskard N, Hill RS et al. Bronchiolitis obliterans complicating bone marrow transplantation. Chest 1985; 87: 828-830.
37. Holland HK, Wingard JR, Beschorner WE et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988; 72: 621-627.
38. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666.
39. Freudenberger TD, Madtes DK, Curtis JR et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003; 102: 3822-3828.
40. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
41. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144: 1202-1218.
42. McFadden Jr ER, Linden DA. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med 1972; 52: 725-737.
43. Cosio M, Ghezzo H, Hogg JC et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
44. McCarthy DS, Craig DB, Cherniack RM. Intraindividual variability in maximal expiratory flow-volume and closing volume in asymptomatic subjects. Am Rev Respir Dis 1975; 112: 407-411.
45. Cochrane GM, Prieto F, Clark TJ. Intrasubject variability of maximal expiratory flow volume curve. Thorax 1977; 32: 171-176.
46. Parimon T, Clark JG, Chien JW. Implication of significant bronchodilator response in patients who develop airflow obstruction after hematopoietic stem cell transplant. Am J Respir Crit Care Med 2004; 169: A93.
47. Cliff IJ, Evans AH, Pantin CF, Baldwin DR. Comparison of two new methods for the measurement of lung volumes with two standard methods. Thorax 1999; 54: 329-333.
48. Blakemore WS, Forster RE, Morton JW, Ogilvie CM. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957; 36: 1-17.
49. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198.
50. Crapo RO, Forster II RE. Carbon monoxide diffusing capacity. Clin Chest Med 1989; 10: 187-198.
51. Yamaguchi K, Mori M, Kawai A et al. Inhomogeneities of ventilation and the diffusing capacity to perfusion in various chronic lung diseases. Am J Respir Crit Care Med 1997; 156: 86-93.
52. Punjabi NM, Shade D, Patel AM, Wise RA. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003; 123: 1082 1089.
53. Clausen J, Crapo RO, Gardner RM. Interlaboratory comparisons of pulmonary function testing. Am Rev Respir Dis 1984; 129 (Suppl): A37.
54. Cotes JE, Dabbs JM, Elwood PC et al. Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci 1972; 42: 325-335.
55. Stam H, Splinter TA, Versprille A. Evaluation of diffusing capacity in patients with a restrictive lung disease. Chest 2000; 117: 752-757.
56. do Pico GA, Wiley Jr AL, Rao P, Dickie HA. Pulmonary reaction to upper mantle radiation therapy for Hodgkin's disease. Chest 1979; 75: 688-692.
57. Badier M, Guillot C, Delpierre S et al. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12: 457-461.
58. Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 36: 67-75.
59. Ghalie R, Szidon JP, Thompson L et al. Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests. Bone Marrow Transplant 1992; 10: 359-365.
60. Schwarer AP, Hughes JM, Trotman-Dickenson B et al. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation 1992; 54: 1002-1008.
61. Matute-Bello G, McDonald GD, Hinds MS et al. Association of pulmonary function testing abnormalities and severe venoocclusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125-1130.
62. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257-1264.
63. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
64. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16: 3796-3802.
65. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
66. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
67. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
68. Fukuda T, Hackman RC, Guthrie KA et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777-2785.